Skip to main content

Table 10 Cost effectiveness analysis of bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%

From: Pharmacoeconomic analysis of prostaglandin and prostamide therapy for patients with glaucoma or ocular hypertension

 

Bimatoprost 0.03%

Latanoprost 0.005%

Travoprost 0.004%

Annual Cost*

$455

$537

$591

IOP Reduction, Lower Value † (mm Hg)

7

6

7

IOP Reduction, Upper Value † (mm Hg)

8

8

8

Cost Effectiveness Range ($/mm Hg decrease in IOP)

$57–$65/mm Hg

$67–$90/mm Hg

$74–$84/mm Hg

  1. IOP = intraocular pressure
  2. *Average retail price, 2005, before adjustment for drug shelf life.
  3. †Ranges of IOP reduction efficacy reported in package inserts [7–9].